Semaglutide
EhBuddy Research-Grade Semaglutide — Available in 5mg, 10mg, 15mg, 20mg, 30mg
Semaglutide is the world's most studied GLP-1 receptor agonist, forming the backbone of modern metabolic, obesity, and cardiovascular research. SUSTAIN and STEP trial data demonstrate profound reductions in body weight (up to 17.4%), HbA1c, and MACE events, establishing Semaglutide as the gold standard reference compound for GLP-1 research.
Reconstitution: Bacteriostatic Water (BAC Water) or Sterile Water required.
FOR RESEARCH USE ONLY (RUO). Not approved for human or veterinary use. Intended for in vitro and laboratory research only. EhBuddy Peptides assumes no liability for misuse.
Tirzepatide
EhBuddy Research-Grade Tirzepatide — Available in 5mg, 10mg, 15mg, 20mg, 30mg, 40mg, 45mg, 50mg, 60mg, 80mg, 100mg
Tirzepatide is a groundbreaking dual GLP-1/GIP receptor agonist that has reshaped metabolic and obesity research. Research models demonstrate up to 22.5% body weight reduction, significant glycaemic improvement, and beneficial effects on cardiovascular risk markers — making it one of the most studied compounds in modern metabolic research.
Reconstitution: Bacteriostatic Water (BAC Water) or Sterile Water required.
FOR RESEARCH USE ONLY (RUO). Not approved for human or veterinary use. Intended for in vitro and laboratory research only. EhBuddy Peptides assumes no liability for misuse.
Retatrutide
Mazdutide
EhBuddy Research-Grade Mazdutide — Available in 5mg, 10mg
Mazdutide (IBI362) is a novel dual GLP-1/glucagon receptor agonist under active clinical investigation for obesity and type 2 diabetes. Phase 2 research data demonstrates exceptional body weight reduction and glycaemic improvements, combining the appetite-suppressing power of GLP-1 with glucagon's thermogenic and lipolytic effects.
Reconstitution: Bacteriostatic Water (BAC Water) or Sterile Water required.
FOR RESEARCH USE ONLY (RUO). Not approved for human or veterinary use. Intended for in vitro and laboratory research only. EhBuddy Peptides assumes no liability for misuse.
Survodutide
EhBuddy Research-Grade Survodutide
Survodutide (BI 456906) is an investigational dual GLP-1/glucagon receptor agonist in Phase 3 trials for obesity and NASH. Research data from the LIGHT UP trials demonstrates substantial body weight reduction along with significant improvements in liver histology — making it one of the most promising compounds in NASH research alongside metabolic syndrome.
Reconstitution: Bacteriostatic Water (BAC Water) or Sterile Water required.
FOR RESEARCH USE ONLY (RUO). Not approved for human or veterinary use. Intended for in vitro and laboratory research only. EhBuddy Peptides assumes no liability for misuse.
GLP-1
EhBuddy Research-Grade GLP-1 (Glucagon-Like Peptide-1) — Research Compound
GLP-1 (7-36 amide) is the endogenous incretin hormone produced by intestinal L-cells in response to food intake — the native peptide target of the entire GLP-1 receptor agonist drug class. As a research tool, native GLP-1 enables study of incretin physiology, GLP-1 receptor biology, and serves as the reference standard for all GLP-1 receptor agonist research compounds including Semaglutide, Tirzepatide, and Retatrutide.
Reconstitution: Bacteriostatic Water (BAC Water) or Sterile Water required.
FOR RESEARCH USE ONLY (RUO). Not approved for human or veterinary use. Intended for in vitro and laboratory research only.
